These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
98 related articles for article (PubMed ID: 7625802)
1. Randomized comparison of meropenem with cefotaxime for treatment of bacterial meningitis. Meropenem Meningitis Study Group. Klugman KP; Dagan R Antimicrob Agents Chemother; 1995 May; 39(5):1140-6. PubMed ID: 7625802 [TBL] [Abstract][Full Text] [Related]
2. A randomised comparison of meropenem with cefotaxime or ceftriaxone for the treatment of bacterial meningitis in adults. Meropenem Meningitis Study Group. Schmutzhard E; Williams KJ; Vukmirovits G; Chmelik V; Pfausler B; Featherstone A J Antimicrob Chemother; 1995 Jul; 36 Suppl A():85-97. PubMed ID: 8543502 [TBL] [Abstract][Full Text] [Related]
3. [The role of meropenem in bacterial meningitis]. Fernández Viladrich P Enferm Infecc Microbiol Clin; 1997 Sep; 15 Suppl 1():57-61. PubMed ID: 9410071 [TBL] [Abstract][Full Text] [Related]
4. Intravenous meropenem versus imipenem/cilastatin in the treatment of serious bacterial infections in hospitalized patients. Meropenem Serious Infection Study Group. Colardyn F; Faulkner KL J Antimicrob Chemother; 1996 Sep; 38(3):523-37. PubMed ID: 8889726 [TBL] [Abstract][Full Text] [Related]
5. Determination of a gentamicin loading dose in neonates and infants. Semchuk W; Borgmann J; Bowman L Ther Drug Monit; 1993 Feb; 15(1):47-51. PubMed ID: 8451781 [TBL] [Abstract][Full Text] [Related]
8. The Blood-Brain Barrier and Pharmacokinetic/Pharmacodynamic Optimization of Antibiotics for the Treatment of Central Nervous System Infections in Adults. Haddad N; Carr M; Balian S; Lannin J; Kim Y; Toth C; Jarvis J Antibiotics (Basel); 2022 Dec; 11(12):. PubMed ID: 36551500 [TBL] [Abstract][Full Text] [Related]
9. RpoE Facilitates Stress-Resistance, Invasion, and Pathogenicity of Fan Y; Bai J; Xi D; Yang B Microorganisms; 2022 Apr; 10(5):. PubMed ID: 35630325 [No Abstract] [Full Text] [Related]
17. Defining responses to therapy and study outcomes in clinical trials of invasive fungal diseases: Mycoses Study Group and European Organization for Research and Treatment of Cancer consensus criteria. Segal BH; Herbrecht R; Stevens DA; Ostrosky-Zeichner L; Sobel J; Viscoli C; Walsh TJ; Maertens J; Patterson TF; Perfect JR; Dupont B; Wingard JR; Calandra T; Kauffman CA; Graybill JR; Baden LR; Pappas PG; Bennett JE; Kontoyiannis DP; Cordonnier C; Viviani MA; Bille J; Almyroudis NG; Wheat LJ; Graninger W; Bow EJ; Holland SM; Kullberg BJ; Dismukes WE; De Pauw BE Clin Infect Dis; 2008 Sep; 47(5):674-83. PubMed ID: 18637757 [TBL] [Abstract][Full Text] [Related]
18. Meropenem: a review of its use in the treatment of serious bacterial infections. Baldwin CM; Lyseng-Williamson KA; Keam SJ Drugs; 2008; 68(6):803-38. PubMed ID: 18416587 [TBL] [Abstract][Full Text] [Related]
19. Experimental study of meropenem in the therapy of cephalosporin-susceptible and -resistant pneumococcal meningitis. Force E; Taberner F; Cabellos C; Ribes S; Domenech A; Tubau F; Viladrich PF; Gudiol F Eur J Clin Microbiol Infect Dis; 2008 Aug; 27(8):685-90. PubMed ID: 18386085 [TBL] [Abstract][Full Text] [Related]